Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 10/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | EEF2K | O00418 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 3/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927207 | 0.89 | CTSA (0.53) | CTSAFFAR1EEF2KCYP26A1 | |
| SCHEMBL5692215 | 0.88 | CTSA (0.57) | CTSAMMP12MMP3MMP9MMP8 | |
| SCHEMBL6099049 | 0.87 | CTSA (0.50) | CTSAFFAR1EEF2KMMP12MMP3 | |
| SCHEMBL3991800 | 0.85 | CTSA (0.56) | CTSAFFAR1EEF2K | |
| SCHEMBL5926925 | 0.84 | CTSA (0.53) | CTSAFFAR1EEF2KCYP26A1SUCNR1 | |
| SCHEMBL5927078 | 0.84 | SUCNR1 (0.56) | CTSAFFAR1EEF2KSUCNR1 | |
| SCHEMBL5926127 | 0.84 | PPARG (0.54) | CTSA | |
| SCHEMBL5927016 | 0.83 | KIFC1 (0.60) | — | |
| SCHEMBL5927170 | 0.83 | UTS2R (0.52) | CTSAEEF2KMMP12SUCNR1 | |
| SCHEMBL3989530 | 0.83 | CTSA (0.48) | CTSAFFAR1EEF2KCYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885FFAR1 1360/4885EEF2K 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.